Skip to main content

Table 1 Characteristics of the study population

From: Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection

  BSI group (n = 11) No BSI group (n = 17) p value
Age (years) 59 [46–61] 54.5 [45–60] 0.80
Sex (male) 7 (64 %, 35–85) 13 (76 %, 53–90) 0.75
Body mass index 24 [22–28] 25 [24–28] 0.90
Antibiotic prophylaxis 9 (82 %, 52–95) 15 (88 %, 65–97) 0.99
Penicillin V 8 (72 %, 49–92) 6 (35 %, 17–59) 0.12
Cotrimoxazole 7 (63 %, 36–85) 12 (70 %, 47–87) 0.99
ICU admission 1 (9.0 %, 1.6–37.7) 2 (11.8 %, 2.0–37.8) 0.99
Days of neutropenia 9.0 [8.5-10.0] 10 [9–11] 0.27
Previous chemotherapy (months) 4.0 [3–7.5] 4 [3–5] 0.44
Previous antibiotic treatment (months) 4.0 [2–5] 4 [3–5] 0.66
Other comorbidities, hypertension 4 (36.4 % 12.7–68.4) 2 (11.8 %, 2.0–37.8) 0.28
Diffuse large B-cell lymphoma 9 (81.8 %, 47.8–96.8) 10 (58.9 %, 36.0–78.4) 0.39
Follicular lymphoma 0 (0.0 %, 0.0–25.8) 2 (11.8 %, 2.0–37.8) 0.67
Burkitt lymphoma 0 (0.0 %, 0.0–25.8) 1 (5.9 %, 1.0–27.0) 0.99
Mantle cell lymphoma 2 (57.1 %, 25.0–84.2) 3 (17.6 %, 6.2–41.0) 0.39
Anaplastic large cell lymphoma 0 (0.0 %, 0.0–25.8) 1 (5.9 %, 1.0–27.0) 0.99
  1. BSI, Bloodstream infection; ICU, Intensive Care Unit; NHL, non-Hodgkin lymphoma
  2. Quantitative data are shown as median [1st and 3rd quartile]; fractional data are shown as mean [lower-upper bounds of 95 % confidence interval]
\